Synopsis
Synopsis
0
USDMF
0
CEP/COS
0
JDMF
0
EU WC
0
KDMF
0
API
0
FDF
0
FDA Orange Book
0
Europe
0
Australia
0
South Africa
0
Listed Dossiers
DRUG PRODUCT COMPOSITIONS
0
EDQM
0
USP
0
JP
0
Others
0
US Patents
0
US Exclusivities
0
Health Canada Patents
0
Data Compilation #PharmaFlow
0
Stock Recap #PipelineProspector
0
Weekly News Recap #Phispers
0
News #PharmaBuzz
US Medicaid
NA
Annual Reports
NA
Finished Drug Prices
NA
1. N-(2-bromo-6-fluorophenyl)-4,5-dihydro-(1h)-imidazol-2-amine
2. Romifidine Monohydrochloride
3. Sedivet
4. Sth 2130
1. 65896-16-4
2. N-(2-bromo-6-fluorophenyl)-4,5-dihydro-1h-imidazol-2-amine
3. Romifidinum
4. Sedivet
5. 2-(2-bromo-6-fluoroanilino)-2-imidazoline
6. Romifidine (inn)
7. Romifidine [inn]
8. 876351l05k
9. Romifidinum [latin]
10. Romifidina [spanish]
11. Romifidina
12. Romifidine [inn:ban]
13. Unii-876351l05k
14. Sedivet (tn)
15. Romifidine [mi]
16. Romifidine [mart.]
17. Mls006010405
18. Schembl246009
19. Chembl2105424
20. Dtxsid40216103
21. Mfcd00868606
22. Zinc56898821
23. Akos026348206
24. Db11543
25. Ncgc00532499-01
26. Smr004701406
27. Hy-119456
28. Cs-0068423
29. R0120
30. 2-(2-bromo-6-fluorophenylamino)-2-imidazoline
31. D08487
32. Methyl4-chloro-3-cyclohexene-1-carboxylate
33. Q747850
34. Sr-01000945279
35. Sr-01000945279-1
36. Z1849014130
Molecular Weight | 258.09 g/mol |
---|---|
Molecular Formula | C9H9BrFN3 |
XLogP3 | 1.4 |
Hydrogen Bond Donor Count | 2 |
Hydrogen Bond Acceptor Count | 2 |
Rotatable Bond Count | 2 |
Exact Mass | 256.99639 g/mol |
Monoisotopic Mass | 256.99639 g/mol |
Topological Polar Surface Area | 36.4 Ų |
Heavy Atom Count | 14 |
Formal Charge | 0 |
Complexity | 234 |
Isotope Atom Count | 0 |
Defined Atom Stereocenter Count | 0 |
Undefined Atom Stereocenter Count | 0 |
Defined Bond Stereocenter Count | 0 |
Undefined Bond Stereocenter Count | 0 |
Covalently Bonded Unit Count | 1 |
Adrenergic alpha-2 Receptor Agonists
Compounds that bind to and activate ADRENERGIC ALPHA-2 RECEPTORS. (See all compounds classified as Adrenergic alpha-2 Receptor Agonists.)
Anesthetics
Agents capable of inducing a total or partial loss of sensation, especially tactile sensation and pain. They may act to induce general ANESTHESIA, in which an unconscious state is achieved, or may act locally to induce numbness or lack of sensation at a targeted site. (See all compounds classified as Anesthetics.)
Related Excipient Companies
ABOUT THIS PAGE
A Romifidine manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of Romifidine, including repackagers and relabelers. The FDA regulates Romifidine manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. Romifidine API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.
click here to find a list of Romifidine manufacturers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PhamaCompass.
A Romifidine supplier is an individual or a company that provides Romifidine active pharmaceutical ingredient (API) or Romifidine finished formulations upon request. The Romifidine suppliers may include Romifidine API manufacturers, exporters, distributors and traders.
click here to find a list of Romifidine suppliers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PharmaCompass.
National Drug Code is a comprehensive database maintained by the FDA that contains information on all drugs marketed in the US. This directory includes information about finished drug products, unfinished drug products, and compounded drug products, including those containing Romifidine as an active pharmaceutical ingredient (API).
The FDA updates the NDC directory daily. The NDC numbers for Romifidine API and other APIs are published in this directory by the FDA.
The NDC unfinished drugs database includes product listing information submitted for all unfinished drugs, such as active pharmaceutical ingredients (APIs), drugs intended for further processing and bulk drug substances for compounding.
Pharmaceutical companies that manufacture Romifidine as an active pharmaceutical ingredient (API) must furnish the FDA with an updated record of all drugs that they produce, prepare, propagate, compound, or process for commercial distribution in the US at their facilities.
The NDC directory also contains data on finished compounded human drug products that contain Romifidine and are produced by outsourcing facilities. While these outsourcing facilities are not mandated to assign a Romifidine NDC to their finished compounded human drug products, they may choose to do so.
click here to find a list of Romifidine suppliers with NDC on PharmaCompass.
Romifidine Active pharmaceutical ingredient (API) is produced in GMP-certified manufacturing facility.
GMP stands for Good Manufacturing Practices, which is a system used in the pharmaceutical industry to make sure that goods are regularly produced and monitored in accordance with quality standards. The FDA’s current Good Manufacturing Practices requirements are referred to as cGMP or current GMP which indicates that the company follows the most recent GMP specifications. The World Health Organization (WHO) has its own set of GMP guidelines, called the WHO GMP. Different countries can also set their own guidelines for GMP like China (Chinese GMP) or the EU (EU GMP).
PharmaCompass offers a list of Romifidine GMP manufacturers, exporters & distributors, which can be sorted by USDMF, JDMF, KDMF, CEP (COS), WC, API price, and more, enabling you to easily find the right Romifidine GMP manufacturer or Romifidine GMP API supplier for your needs.
A Romifidine CoA (Certificate of Analysis) is a formal document that attests to Romifidine's compliance with Romifidine specifications and serves as a tool for batch-level quality control.
Romifidine CoA mostly includes findings from lab analyses of a specific batch. For each Romifidine CoA document that a company creates, the USFDA specifies specific requirements, such as supplier information, material identification, transportation data, evidence of conformity and signature data.
Romifidine may be tested according to a variety of international standards, such as European Pharmacopoeia (Romifidine EP), Romifidine JP (Japanese Pharmacopeia) and the US Pharmacopoeia (Romifidine USP).
LOOKING FOR A SUPPLIER?